View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsOxford Cannabinoid Technologies Holdings 과거 순이익 실적과거 기준 점검 0/6Oxford Cannabinoid Technologies Holdings의 연간 평균 수익은 23.6%였으며, Pharmaceuticals 산업의 수익은 연간 12.2% 증가했습니다.핵심 정보23.57%순이익 성장률23.58%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률n/a자기자본이익률-217.39%순이익률n/a최근 순이익 업데이트31 Oct 2023최근 과거 실적 업데이트공고 • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024공고 • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023모든 업데이트 보기Recent updates공고 • May 09Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official ListThe Board of Oxford Cannabinoid Technologies Holdings plc announced that it has applied to the Financial Conduct Authority ("FCA") and London Stock Exchange plc ("LSE") to effect a cancellation of listing of its ordinary shares on the Standard segment of the FCA's Official List (the "Standard List") and trading on the Main Market for listed securities of the LSE ("Main Market") ("Cancellation"). As a Standard Listed company, OCT is not required to obtain the approval of shareholders for the Cancellation. Pursuant to Listing Rule 5.2.8R, the Company is required to give at least 20 business days' notice of the intended cancellation of its listing. It is therefore anticipated that the Cancellation will become effective at 8.00am on 6 June 2024. Following the Cancellation, the Company will no longer be subject to the regulatory and statutory regime which applies to companies admitted to the Standard segment of the Official List and traded on the Main Market.공고 • Feb 29+ 1 more updateOxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024Oxford Cannabinoid Technologies Holdings plc announced the following Board changes. Bishrut Mukherjee, Non-Executive Director, has notified the board of his intention to step down from his role in order to focus on other business interests. Bishrut has served the Company for over five years, since joining OCT in January 2019. Richard Hathaway, Non-Executive Director, has also notified the board of his intention to step down from his role in order to be able to devote more time to his other duties and responsibilities as Corporate Development Director at Imperial Brands plc ("Imperial"). Richard joined the board of OCT in February 2022 as a representative of Imperial Brands Ventures Limited, a wholly owned subsidiary of Imperial. Imperial remains a significant and supportive shareholder of the Company and Richard will continue in his role as shareholder liaison. Bishrut and Richard will leave the Company on 31 March 2024.공고 • Feb 15Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million.Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 128,000,000 Price\Range: £0.005 Transaction Features: Subsequent Direct Listing공고 • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024공고 • Jan 10Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2Oxford Cannabinoid Technologies Holdings plc announced that it has filed a European application in its own name, directed to Programme 2. This programme initially targets Trigeminal Neuralgia ("TN"), and the patent application filed by the Company is directed to a composition containing Delta-9-tetrahydrocannabinol and Cannabidiol. The Company intends to file an international ("PCT") patent application based on this European application within the next year. Once the patent is granted, OCTP will benefit from exclusive rights to the use, production, and sale of the composition claimed in the patent, typically for a period of up to 20 years from the filing date. This protection potentially allows OCTP to recoup its investment in R&D and secure a competitive market advantage. Patent application examination times can vary, but grant of the patent can typically be expected in 2 to 5 years from the filing date of the patent application. The precise timing will depend on the examination process at the patent office and any objections or oppositions that may arise. The Company expects to file several other patent applications directed to other aspects of Programme 2 during 2024.공고 • Nov 15Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive DirectorOxford Cannabinoid Technologies Holdings plc announced the following Board appointment. The Company announced the appointment of Dr. Tim Corn, Chief Medical Officer (CMO), as an executive director, effective immediately. As announced on 8 June 2023, Dr. Corn joined OCTP as CMO to oversee the Company's clinical research and development activities as well as to provide expert medical guidance and advice to the team. Since joining, the Company has successfully completed its first Phase I clinical trial, a single ascending dose study of its lead compound OCT461201. Dr. Corn, formerly Chief Medical Officer International at Jazz Pharmaceuticals plc, has played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists.공고 • Oct 10Oxford Cannabinoid Technologies Holdings plc Announces Phase I Clinical Trial Results for Lead Drug Candidate OCT461201Oxford Cannabinoid Technologies Holdings plc announced that dosing of all the cohorts of the Phase I, single ascending dose study for OCT461201 has been successfully completed. No safety or tolerability concerns were exhibited with any dose tested. As a result, OCTP is satisfied that it is safe to proceed to the next stage of clinical development of its lead compound OCT461201. The trial was conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was administered on 20 September 2023, followed by formal review of final clinical data on 2 October 2023. The trial's primary objective was to demonstrate the safety and tolerability of OCT461201, whilst also providing important information on its pharmacokinetic profile.공고 • Sep 25Oxford Cannabinoid Technologies Holdings plc Announces Final Dose Administered in Phase I Clinical TrialOxford Cannabinoid Technologies Holdings plc announced that the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered, as part of its Phase I clinical trial, with no drug adverse effects observed. The trial is being conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was successfully administered on 20 September 2023, in line with the Company's previously announced timeframe. The trial's principal objective is to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The Company expects to report results by 16 October 2023.공고 • Sep 01Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023, at 10:00 Coordinated Universal Time. Location: Penningtons Manches Cooper LLP at 125 Wood Street, London London United Kingdom공고 • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023공고 • Jul 18Oxford Cannabinoid Technologies Holdings plc Announces Expansion into Oncology Potential New Cannabinoid-Based Treatment of Cancer MalignanciesOxford Cannabinoid Technologies Holdings plc is formally expanding its research and development strategy into oncology having identified a potential "first in class" immunotherapy agent for the treatment of solid tumours. The Company's analysis of the initial data shows excellent drug-like potential in terms of in vitro potency and selectivity to target, as well as in vivo availability in blood. This implies substantive potential for the development of a cannabinoid-based medicine that could be taken at home, as a tablet. The asset has arisen from the work being carried out on OCTP's cannabinoid library of almost 500 derivatives for the Company's Programme 4 and further demonstrates the value in OCTP's exclusive licence agreement with Canopy Growth Corporation. At this early stage of development, management believes the potency shown on the selected target in vitro, in addition to its in vivo behaviour, demonstrates significant potential. attention will now focus on further in vitro and in vivo studies to highlight the full potential of this lead-cand candidate. This will be followed by a safety-pharmacology assessment before final candidate selection, likely during 2024. This work will be carried out using the existing cash resources of the Company. The OCTP team has discovered a potential first-line-treatment alternative to existing therapies and their side effects which could provide a viable alternative to expensive biologics. Although the company're at an early stage, this is exciting news for the Company. As the potential of cannabinoid-based medicines to treat a range of conditions in a less harmful and more economic manner receives growing public recognition, OCTP stands at the forefront of research & development and company are extremely excited to have identified a possible candidate that could have a significant impact on many people' lives.공고 • Jun 09Oxford Cannabinoid Technologies Holdings plc Announces Appointment of Tim Corn as Chief Medical OfficerOxford Cannabinoid Technologies Holdings plc announced the appointment of Dr. Tim Corn as the Company's new Chief Medical Officer effective immediately. Dr. Corn is an independent pharmaceuticals consultant who has held senior positions in both large and small pharma organisations. He is currently CMO at Nodenza Inc. and Medical Adviser to Confo Therapeutics SA, which recently announced a global licensing deal with Eli Lilly and Company for the clinical stage peripheral pain candidate CFTX-1554 and back-up compounds. He also serves as a non-executive director on the Board of Physiomics plc. He was formerly Chief Medical Officer International at Jazz Pharmaceuticals plc and CMO at venture-backed companies EUSA Pharma Inc, acquired by Jazz Pharmaceuticals plc in 2012, and Zeneus Pharma Ltd, acquired by Cephalon Inc. in 2005. Dr Corn has also played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists. Dr. Corn will oversee the Company's clinical research and development activities as well as providing expert medical guidance and advice to the team.공고 • May 19Oxford Cannabinoid Technologies Holdings plc Announces Mhra and Rec 2 Approval of Phase I Clinical Trial ApplicationOxford Cannabinoid Technologies Holdings Plc announced that the Medicines and Healthcare Products Regulatory Agency ("MHRA") and the Wales Research Ethics Committee 2 ("REC 2") have approved the Company's combined Phase I clinical trial application for OCTP's lead drug candidate, OCT461201. This Phase I first-in-human clinical trial is being conducted in the UK in healthy volunteers, with a single ascending dose protocol. The trial is being conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd. ("Simbec-Orion") and aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. Participants enrolment will begin immediately, and the trial is expected to be completed during Third Quarter 2023. The trial is being funded entirely from OCTP's existing resources. Growing global opportunity OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone is currently valued at USD 1.61 billion and is forecast to reach USD 2.37 billion by 2027.공고 • Jan 16Oxford Cannabinoid Technologies Holdings plc Announces Appointment of General Counsel and Company SecretaryOxford Cannabinoid Technologies Holdings plc, for approval by global regulatory agencies and targeting the USD multi-billion pain market, announced the appointment of Robin ("Rob") Bennett as General Counsel and Company Secretary. Rob joined the Company in December 2022 as General Counsel and was appointed Company Secretary on 12 January 2023. Rob brings a wealth of experience and expertise to the Company from his role as General Counsel and Company Secretary at Bestway Wholesale (formerly Costcutter Supermarkets Group). He has over 15 years of UK and international experience across multiple sectors, including retail, fast-moving consumer goods, manufacturing, innovation and FinTech. His knowledge in legal, risk and compliance has been gained through working with SMEs and quoted companies such as SABMiller plc. He has been recognised for his work by being listed in Legal 500's GC Powerlists in 2021 and 2022 and as a Team of the Year finalist at The Lawyer Awards in 2021.공고 • Jan 06Oxford Cannabinoid Technologies Holdings plc Submits Combined Clinical Trials Application for Its Lead Programme, OCT461201Oxford Cannabinoid Technologies Holdings plc announced that on 4 January 2023 it submitted a combined clinical trials application for its lead programme, OCT461201, to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee (REC) 2 (the Submission) in preparation for a review meeting to be held on 11 January 2023. The Submission follows the successful completion of OCTP's extensive pre-clinical work on OCT461201, under the Group's £2.6 million contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE. OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone was valued at USD 1.61 billion in 2020 and is forecast to reach USD 2.37 billion by the year 2027. This Phase I first-in-human clinical trial, due to commence in first quarter 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within second quarter 2023.매출 및 비용 세부 내역Oxford Cannabinoid Technologies Holdings가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:OCTH.F 매출, 비용 및 순이익 (GBP Millions)날짜매출순이익일반관리비연구개발비31 Oct 230-43031 Jul 230-53030 Apr 230-63030 Apr 220-530양질의 수익: OCTH.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: OCTH.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 OCTH.F의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 OCTH.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: OCTH.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: OCTH.F는 현재 수익성이 없으므로 자본 수익률이 음수(-217.39%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/08/05 13:30종가2024/05/08 00:00수익2023/10/31연간 수익2023/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Oxford Cannabinoid Technologies Holdings Plc는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Soo RomanoffEdison Investment Research
공고 • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024
공고 • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023
공고 • May 09Oxford Cannabinoid Technologies Intends Cancellation of Listing of its Ordinary Shares on the Standard Segment of the FCA's Official ListThe Board of Oxford Cannabinoid Technologies Holdings plc announced that it has applied to the Financial Conduct Authority ("FCA") and London Stock Exchange plc ("LSE") to effect a cancellation of listing of its ordinary shares on the Standard segment of the FCA's Official List (the "Standard List") and trading on the Main Market for listed securities of the LSE ("Main Market") ("Cancellation"). As a Standard Listed company, OCT is not required to obtain the approval of shareholders for the Cancellation. Pursuant to Listing Rule 5.2.8R, the Company is required to give at least 20 business days' notice of the intended cancellation of its listing. It is therefore anticipated that the Cancellation will become effective at 8.00am on 6 June 2024. Following the Cancellation, the Company will no longer be subject to the regulatory and statutory regime which applies to companies admitted to the Standard segment of the Official List and traded on the Main Market.
공고 • Feb 29+ 1 more updateOxford Cannabinoid Technologies Holdings plc Announces Board Changes, Effective 31 March 2024Oxford Cannabinoid Technologies Holdings plc announced the following Board changes. Bishrut Mukherjee, Non-Executive Director, has notified the board of his intention to step down from his role in order to focus on other business interests. Bishrut has served the Company for over five years, since joining OCT in January 2019. Richard Hathaway, Non-Executive Director, has also notified the board of his intention to step down from his role in order to be able to devote more time to his other duties and responsibilities as Corporate Development Director at Imperial Brands plc ("Imperial"). Richard joined the board of OCT in February 2022 as a representative of Imperial Brands Ventures Limited, a wholly owned subsidiary of Imperial. Imperial remains a significant and supportive shareholder of the Company and Richard will continue in his role as shareholder liaison. Bishrut and Richard will leave the Company on 31 March 2024.
공고 • Feb 15Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million.Oxford Cannabinoid Technologies Holdings Plc has completed a Follow-on Equity Offering in the amount of £0.64 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 128,000,000 Price\Range: £0.005 Transaction Features: Subsequent Direct Listing
공고 • Jan 23Oxford Cannabinoid Technologies Holdings Plc to Report First Half, 2024 Results on Jan 30, 2024Oxford Cannabinoid Technologies Holdings Plc announced that they will report first half, 2024 results on Jan 30, 2024
공고 • Jan 10Oxford Cannabinoid Technologies Holdings plc Files A European Application in Own Name, Directed to Programme 2Oxford Cannabinoid Technologies Holdings plc announced that it has filed a European application in its own name, directed to Programme 2. This programme initially targets Trigeminal Neuralgia ("TN"), and the patent application filed by the Company is directed to a composition containing Delta-9-tetrahydrocannabinol and Cannabidiol. The Company intends to file an international ("PCT") patent application based on this European application within the next year. Once the patent is granted, OCTP will benefit from exclusive rights to the use, production, and sale of the composition claimed in the patent, typically for a period of up to 20 years from the filing date. This protection potentially allows OCTP to recoup its investment in R&D and secure a competitive market advantage. Patent application examination times can vary, but grant of the patent can typically be expected in 2 to 5 years from the filing date of the patent application. The precise timing will depend on the examination process at the patent office and any objections or oppositions that may arise. The Company expects to file several other patent applications directed to other aspects of Programme 2 during 2024.
공고 • Nov 15Oxford Cannabinoid Technologies Holdings plc Appoints Tim Corn as an Executive DirectorOxford Cannabinoid Technologies Holdings plc announced the following Board appointment. The Company announced the appointment of Dr. Tim Corn, Chief Medical Officer (CMO), as an executive director, effective immediately. As announced on 8 June 2023, Dr. Corn joined OCTP as CMO to oversee the Company's clinical research and development activities as well as to provide expert medical guidance and advice to the team. Since joining, the Company has successfully completed its first Phase I clinical trial, a single ascending dose study of its lead compound OCT461201. Dr. Corn, formerly Chief Medical Officer International at Jazz Pharmaceuticals plc, has played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists.
공고 • Oct 10Oxford Cannabinoid Technologies Holdings plc Announces Phase I Clinical Trial Results for Lead Drug Candidate OCT461201Oxford Cannabinoid Technologies Holdings plc announced that dosing of all the cohorts of the Phase I, single ascending dose study for OCT461201 has been successfully completed. No safety or tolerability concerns were exhibited with any dose tested. As a result, OCTP is satisfied that it is safe to proceed to the next stage of clinical development of its lead compound OCT461201. The trial was conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was administered on 20 September 2023, followed by formal review of final clinical data on 2 October 2023. The trial's primary objective was to demonstrate the safety and tolerability of OCT461201, whilst also providing important information on its pharmacokinetic profile.
공고 • Sep 25Oxford Cannabinoid Technologies Holdings plc Announces Final Dose Administered in Phase I Clinical TrialOxford Cannabinoid Technologies Holdings plc announced that the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered, as part of its Phase I clinical trial, with no drug adverse effects observed. The trial is being conducted in the UK in healthy volunteers by Simbec Research Limited, part of Simbec-Orion Group Ltd, using a single ascending dose protocol. The final dose was successfully administered on 20 September 2023, in line with the Company's previously announced timeframe. The trial's principal objective is to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The Company expects to report results by 16 October 2023.
공고 • Sep 01Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023Oxford Cannabinoid Technologies Holdings Plc, Annual General Meeting, Sep 28, 2023, at 10:00 Coordinated Universal Time. Location: Penningtons Manches Cooper LLP at 125 Wood Street, London London United Kingdom
공고 • Aug 22Oxford Cannabinoid Technologies Holdings Plc to Report Fiscal Year 2023 Results on Aug 31, 2023Oxford Cannabinoid Technologies Holdings Plc announced that they will report fiscal year 2023 results on Aug 31, 2023
공고 • Jul 18Oxford Cannabinoid Technologies Holdings plc Announces Expansion into Oncology Potential New Cannabinoid-Based Treatment of Cancer MalignanciesOxford Cannabinoid Technologies Holdings plc is formally expanding its research and development strategy into oncology having identified a potential "first in class" immunotherapy agent for the treatment of solid tumours. The Company's analysis of the initial data shows excellent drug-like potential in terms of in vitro potency and selectivity to target, as well as in vivo availability in blood. This implies substantive potential for the development of a cannabinoid-based medicine that could be taken at home, as a tablet. The asset has arisen from the work being carried out on OCTP's cannabinoid library of almost 500 derivatives for the Company's Programme 4 and further demonstrates the value in OCTP's exclusive licence agreement with Canopy Growth Corporation. At this early stage of development, management believes the potency shown on the selected target in vitro, in addition to its in vivo behaviour, demonstrates significant potential. attention will now focus on further in vitro and in vivo studies to highlight the full potential of this lead-cand candidate. This will be followed by a safety-pharmacology assessment before final candidate selection, likely during 2024. This work will be carried out using the existing cash resources of the Company. The OCTP team has discovered a potential first-line-treatment alternative to existing therapies and their side effects which could provide a viable alternative to expensive biologics. Although the company're at an early stage, this is exciting news for the Company. As the potential of cannabinoid-based medicines to treat a range of conditions in a less harmful and more economic manner receives growing public recognition, OCTP stands at the forefront of research & development and company are extremely excited to have identified a possible candidate that could have a significant impact on many people' lives.
공고 • Jun 09Oxford Cannabinoid Technologies Holdings plc Announces Appointment of Tim Corn as Chief Medical OfficerOxford Cannabinoid Technologies Holdings plc announced the appointment of Dr. Tim Corn as the Company's new Chief Medical Officer effective immediately. Dr. Corn is an independent pharmaceuticals consultant who has held senior positions in both large and small pharma organisations. He is currently CMO at Nodenza Inc. and Medical Adviser to Confo Therapeutics SA, which recently announced a global licensing deal with Eli Lilly and Company for the clinical stage peripheral pain candidate CFTX-1554 and back-up compounds. He also serves as a non-executive director on the Board of Physiomics plc. He was formerly Chief Medical Officer International at Jazz Pharmaceuticals plc and CMO at venture-backed companies EUSA Pharma Inc, acquired by Jazz Pharmaceuticals plc in 2012, and Zeneus Pharma Ltd, acquired by Cephalon Inc. in 2005. Dr Corn has also played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists. Dr. Corn will oversee the Company's clinical research and development activities as well as providing expert medical guidance and advice to the team.
공고 • May 19Oxford Cannabinoid Technologies Holdings plc Announces Mhra and Rec 2 Approval of Phase I Clinical Trial ApplicationOxford Cannabinoid Technologies Holdings Plc announced that the Medicines and Healthcare Products Regulatory Agency ("MHRA") and the Wales Research Ethics Committee 2 ("REC 2") have approved the Company's combined Phase I clinical trial application for OCTP's lead drug candidate, OCT461201. This Phase I first-in-human clinical trial is being conducted in the UK in healthy volunteers, with a single ascending dose protocol. The trial is being conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd. ("Simbec-Orion") and aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. Participants enrolment will begin immediately, and the trial is expected to be completed during Third Quarter 2023. The trial is being funded entirely from OCTP's existing resources. Growing global opportunity OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone is currently valued at USD 1.61 billion and is forecast to reach USD 2.37 billion by 2027.
공고 • Jan 16Oxford Cannabinoid Technologies Holdings plc Announces Appointment of General Counsel and Company SecretaryOxford Cannabinoid Technologies Holdings plc, for approval by global regulatory agencies and targeting the USD multi-billion pain market, announced the appointment of Robin ("Rob") Bennett as General Counsel and Company Secretary. Rob joined the Company in December 2022 as General Counsel and was appointed Company Secretary on 12 January 2023. Rob brings a wealth of experience and expertise to the Company from his role as General Counsel and Company Secretary at Bestway Wholesale (formerly Costcutter Supermarkets Group). He has over 15 years of UK and international experience across multiple sectors, including retail, fast-moving consumer goods, manufacturing, innovation and FinTech. His knowledge in legal, risk and compliance has been gained through working with SMEs and quoted companies such as SABMiller plc. He has been recognised for his work by being listed in Legal 500's GC Powerlists in 2021 and 2022 and as a Team of the Year finalist at The Lawyer Awards in 2021.
공고 • Jan 06Oxford Cannabinoid Technologies Holdings plc Submits Combined Clinical Trials Application for Its Lead Programme, OCT461201Oxford Cannabinoid Technologies Holdings plc announced that on 4 January 2023 it submitted a combined clinical trials application for its lead programme, OCT461201, to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee (REC) 2 (the Submission) in preparation for a review meeting to be held on 11 January 2023. The Submission follows the successful completion of OCTP's extensive pre-clinical work on OCT461201, under the Group's £2.6 million contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE. OCT461201 is a selective cannabinoid receptor type 2 agonist which has shown potential as an effective therapy for chemotherapy induced peripheral neuropathy ("CIPN") as well as irritable bowel syndrome ("IBS"). The global market for CIPN alone was valued at USD 1.61 billion in 2020 and is forecast to reach USD 2.37 billion by the year 2027. This Phase I first-in-human clinical trial, due to commence in first quarter 2023, which is being funded entirely from OCTP's existing resources, will be conducted in the UK in healthy volunteers, with a single ascending dose. The trial aims to demonstrate the safety and tolerability of OCT461201, whilst also providing pivotal information on its pharmacokinetic profile, to confirm its value as a potential drug. The clinical trial is anticipated to complete within second quarter 2023.